Share

Meet the new EORTC Board

The year 2024 signals the beginning of a new governing mandate. We are delighted to announce that during the General Assembly held on Friday, 28 June 2024, the new EORTC Board was appointed.

We warmly welcome four distinguished new members to our Board: Mrs Caroline Artis, the new Chair of the Audit & Finance Committee; Dr Roberto Salgado, who joins as a board member; Professor Martin van den Bent, the new Chair of the Protocol Review Committee; and Early Career Investigator, Dr Jens Lehmann.

Additionally, we are pleased to announce that Dr Etienne Brain and Dr Mieke Van Hemelrijck have been re-elected for a second term, and Dr Jean-Pierre Bizzari will now serve as Special Advisor. The rest of the board members have been renewed in their current roles.

The full new Board will convene for the first time in September. The current President, Professor W. van der Graaf, will remain in position until June 2026, as approved by the General Assembly, ensuring continuity during the recent changes in the EORTC’s governance structure.

Back to news list

Related News

  • EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

  • Minister F. Vandenbroucke visits EORTC Headquarters to strengthen collaborative efforts in clinical cancer research

  • IMMUcan has completed patient enrolment

  • EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients

  • Pink October at EORTC: Over 60 years of impactful breast cancer research

  • Spotlight on ENA 2024 News

  • Do regulations and policies undermine the social value of independent academic research?

  • EORTC Quality of Life Group’s participation to ISOQOL 2024

  • New Insights into Glioblastoma Treatment for Older Adults Patients

  • TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival